论文部分内容阅读
目的:观察醒脑静注射液联合依达拉奉治疗急性脑出血的临床疗效和安全性。方法:急性脑出血患者120例随机分为观察组和对照组。在常规对症治疗基础上,对照组予依达拉奉30 mg+0.9%氯化钠注射液100 ml,ivd,bid,观察组在对照组基础上再加用醒脑静注射液20 ml+5%葡萄糖注射液250 ml,ivd,qd。疗程均为2周。观察比较两组疗效、NIHSS评分、BI评分、C反应蛋白水平及药品不良反应。结果:观察组疗效明显优于对照组(70.00%vs 43.33%,P<0.05)。治疗后,两组NIHSS评分与C反应蛋白水平均较治疗前明显降低,而BI评分均较治疗前明显升高(P<0.05);且观察组与对照组NIHSS评分、BI评分和C反应蛋白水平比较,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(10.00%vs 3.33%,P>0.05)。结论:醒脑静注射液联合依达拉奉治疗急性脑出血,疗效确切,安全性佳,能有效恢复患者神经功能。
Objective: To observe the clinical effect and safety of xingnaojing injection combined with edaravone in the treatment of acute cerebral hemorrhage. Methods: 120 patients with acute cerebral hemorrhage were randomly divided into observation group and control group. On the basis of routine symptomatic treatment, the control group was given edaravone 30 mg + 0.9% sodium chloride injection 100 ml, ivd, bid, the observation group in addition to the control group plus Xingnaojing injection 20 ml +5 % Glucose injection 250 ml, ivd, qd. The course of treatment is 2 weeks. The curative effect, NIHSS score, BI score, C-reactive protein level and adverse drug reactions were observed and compared between the two groups. Results: The observation group was significantly better than the control group (70.00% vs 43.33%, P <0.05). After treatment, NIHSS score and C-reactive protein level in both groups were significantly lower than those before treatment, while BI scores were significantly higher than those before treatment (P <0.05); NIHSS score, BI score and C-reactive protein The differences were statistically significant (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (10.00% vs 3.33%, P> 0.05). Conclusion: Xingnaojing injection combined with edaravone in treatment of acute intracerebral hemorrhage has definite curative effect and good safety, which can effectively restore the neurological function of patients.